Britain and America have hammered out a key trade agreement that will keep no tariffs on UK medicine exports going into the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these key exports will remain at nothing for a duration of the next three years.
This deal comes after recent statements to hike import taxes on branded pharmaceutical imports, with increases floated reaching double the cost.
"This arrangement with the UK bolsters the international landscape for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," an announcement declared.
Commercial Importance
Pharmaceuticals are one of the Britain's largest goods shipped to the US, which is clearly the primary destination for major UK drugmakers.
Statistics reveal that in the year leading up to last September, the UK shipped drugs totaling over eleven billion pounds to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This agreement protects jobs, stimulates funding and facilitates the UK to emerge as a worldwide center for medical research," a minister remarked.
Key British Pledges
The agreement involves several notable changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise overall public funding on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments exceeded 20%.
Broader Context
The deal comes amid a protracted tension between the sector and the ministers over drug pricing and approval rates.
These tensions were intensified by arguments that US customers were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or abandoned, while substantial investments have been announced toward American operations.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
